Bird Flu News and Research RSS Feed - Bird Flu News and Research Twitter

Viewpoints: 'Entitlement meltdown;' improving Medicare Advantage; 'sloppy work habits' at CDC

Viewpoints: 'Entitlement meltdown;' improving Medicare Advantage; 'sloppy work habits' at CDC

Each day, 10,000 baby boomers retire and begin receiving Medicare and Social Security benefits. And while five workers supported the benefits of each retiree in 1960, there will be only two workers funding each retiree by 2030. Those who dismiss long-term budget projections should re-read the last paragraph. The retirement of 77 million baby boomers into Social Security and Medicare is not a theoretical projection. Demography is destiny (Sen. Rob Portman, R-Ohio, 7/21). [More]
First Edition: July 18, 2014

First Edition: July 18, 2014

Today's headlines include reports from the marketplace, including UnitedHealthcare's move toward the health law's insurance marketplaces and the latest on the Securities and Exchange Commission investigation into insider trading related to a health policy change. [More]
CDC closes labs after anthrax, flu accidents

CDC closes labs after anthrax, flu accidents

Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs. [More]
First Edition: July 14, 2014

First Edition: July 14, 2014

Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail. [More]
Patient choice and hospital capacity during pandemic

Patient choice and hospital capacity during pandemic

Allowing patients to choose which hospital they attend when suffering illness during a pandemic rather than assigning them to a specific healthcare facility is appealing to patients during such a crisis. However, such a patient-centric hospital capacity management is conventionally viewed as inefficient system-wide. [More]
Leopoldina, DFG present joint recommendations for handling security-relevant scientific research

Leopoldina, DFG present joint recommendations for handling security-relevant scientific research

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the German National Academy of Sciences Leopoldina presented their joint recommendations on "Scientific Freedom and Scientific Responsibility" on 26 June 2014 in Berlin. [More]
Researchers map risk of H7N9 bird flu infection in markets across Asia

Researchers map risk of H7N9 bird flu infection in markets across Asia

Led by Marius Gilbert - Interfaculty School of Bioengineering, Université libre de Bruxelles - an international researcher team maps the risk of H7N9 bird flu infection in markets across Asia. The identification of high risk areas should helping to restrict the spread of this new disease. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
Travel and socialization patterns give greater insight into spread of new diseases in humans

Travel and socialization patterns give greater insight into spread of new diseases in humans

Scientists at the University of Liverpool have shown how the travel and socialisation patterns of people in Southern China can give greater insight into how new diseases such as bird flu may spread between populations. [More]
Biotech to the rescue

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal. [More]
Study finds ginseng can help prevent, treat influenza and RSV infection

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences. [More]
PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Frost & Sullivan: Healthcare acquired infections drive hand hygiene market in Western Europe

Frost & Sullivan: Healthcare acquired infections drive hand hygiene market in Western Europe

The need to prevent and control healthcare acquired infections (HCAI) across Europe, which results in 4.5 to 5 million cases annually, is driving the hand hygiene market in Western Europe. Outbreaks of norovirus and bird flu over the past five years have also served to highlight the importance of hand hygiene in containing infectious diseases. Hand hygiene product manufacturers should take advantage of these trends by offering a one-stop solution for all disinfection requirements. [More]
Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). [More]
Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

The habit of Googling for an online diagnosis before visiting a GP can provide early warning of an infectious disease epidemic. [More]
New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications. [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide. [More]